NCT01022255已完成1 期
Phase I Study of an Autologous Recombinant Idiotypic Vaccine Manufactured by magnICON® Technology for the Treatment of Patients With Relapsed or Transformed Follicular Lymphoma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 3
- 主要终点
- Proportion of patients with toxicities as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI/CTCAE) version 3.0 grade >/= 3 to the magnICON generated idiotype (Id) vaccine
研究概览
简要总结
This phase I study will evaluate the safety and tolerability of an autologous idiotype vaccine manufactured by magnICON technology for patients with relapsed follicular lymphoma who are in complete or partial remission following non-antiCD20 containing salvage therapy. Data in terms of idiotype-specific immune responses will also be obtained.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with histologically proven follicular lymphoma (grade 1, 2, or 3a), in clinical relapse/progression requiring treatment
- •Subjects must have had first line treatment consisting of rituximab with or without rituximab maintenance therapy (i.e. rituximab monotherapy, R-CHOP, R-CVP, R-FND, etc)
- •At least 4 months since last rituximab exposure
- •Subjects may have had any number of prior treatment regimens. If enrolled with transformed follicular lymphoma, study subject must have had anthracycline in a previous regimen
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- •Life expectancy of at least 12 months
- •Presence of at least a 2x2 cm in diameter lymph node (either a single lymph node or combined volume of lymphoid tissue) accessible for excision; for histological confirmation of diagnosis and for manufacture of the vaccine
- •Measurable disease in neck, chest, abdomen, or pelvis as assessed by computed tomography (CT) scan such that response to 2nd line chemotherapy can be defined by the criteria of Cheson et al (JCO 2007; 25:579, see appendix 15.2 and ref 65). PET scan results are not required for enrollment
排除标准
- •Exposure to rituximab or antiCD-20 directed therapy within the 4 months prior to enrollment
- •History of human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection
- •Active clinically serious infections (> grade 2 National Cancer Institute Common Toxic Criteria [NCI-CTC] version 3.0)
- •Symptomatic metastatic brain or meningeal tumors including lymphoma unless the patient is > 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry
- •History of organ allograft
- •Patients undergoing renal dialysis
结局指标
主要结局
Proportion of patients with toxicities as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI/CTCAE) version 3.0 grade >/= 3 to the magnICON generated idiotype (Id) vaccine
时间窗: One month after sixth vaccination (=7 month after achievement of tumour remission and recovery of normal blood values)
次要结局
- Assessment of cellular idiotype-specific immune responses(One month after sixth vaccination (=7 month after achievement of tumour remission and recovery of normal blood values))
- Assessment of humoral idiotype-specific immune responses(One month after sixth vaccination (=7 month after achievement of tumour remission and recovery of normal blood values))
- Long-term safety/tolerability as determined by the proportion of patients with toxicities as assessed by the FDA CBER Guidance for Industry Toxicity Grading Scale in Preventive Vaccine Clinical Trials and the NCI/CTCAE version 4.02 grade >/= 3(Up to the conclusion of a 12 cycle vaccination phase (month 16))
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy AdultsVirus DiseasesNCT04758962GlaxoSmithKline10
进行中（未招募）
1 期
A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster VaccineHerpes Zoster (HZ)ShinglesInfectious DiseaseNCT05871541Immorna Biotherapeutics, Inc.75
已完成
1 期
A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month PreviouslyTuberculosisNCT00427453University of Oxford12
已完成
1 期
Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent GlioblastomaGlioblastomaAstrocytomaGliomaBrain TumorGlioblastoma MultiformeNCT02010606Cedars-Sinai Medical Center39
终止
1 期
Pilot Study of GVAX in Colorectal Cancer CellsColorectal CancerNCT01952730Massachusetts General Hospital1